Skip to main content
Premium Trial:

Request an Annual Quote

Wellcome Trust Center Using GenoLogics' Data Management Tools

NEW YORK (GenomeWeb News) — The UK's Wellcome Trust will use GenoLogics' lab and data management solution in its next-generation sequencing and disease research programs, the company said today.

The Wellcome Trust Centre for Human Genetics will use the company's Geneus platform in its studies seeking the genetic basis of multi-factorial diseases such as diabetes, heart disease, multiple sclerosis, hypertension, and psychiatric disorders.

WTCHG chose the software "because of its flexibility to automate data capture from a wide range of genomics instruments and applications, while allowing us to more efficiently track samples and QC results across numerous projects," WTCHG Head of Genomics Ioannis Ragoussis said in a statement.

Ragoussis also said that the "primary consideration" in using the Geneus platform was its capability to "fully integrate our next-generation sequencing instruments from Illumina and Roche, and automatically pipeline data for downstream analysis."

The Genomics Group also provides services for other University of Oxford groups in areas of interest, such as microarray, high-throughput quantitative gene expression, high-throughput genotyping, and other specialties.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.